Malignant Pleural Mesothelioma Market

Market Overview:

The 7 major malignant pleural mesothelioma markets reached a value of US$ 318.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 632.6 Million by 2034, exhibiting a growth rate (CAGR) of 6.45% during 2024-2034.

The malignant pleural mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Malignant Pleural Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant pleural mesothelioma refers to a type of cancer that develops in the pleura, a tissue covering the lungs and chest wall. Depending on the types of cells in the mesothelium where the malignancy begins, this disease is categorized into epithelioid, sarcomatoid, and biphasic mesothelioma. The primary symptoms of the ailment include ongoing shortness of breath and chest pain. Individuals suffering from malignant pleural mesothelioma may also experience persistent cough, hoarseness, difficulty swallowing, lower back pain, swollen face and arms, unexplained weight loss, night sweats, fatigue, fever, etc. The diagnosis of this disease is based on a physical exam, blood tests, a review of the patient's medical history, and an assessment of risk factors. The healthcare provider may perform various diagnostic procedures, including chest X-rays, magnetic resonance imaging, positron emission tomography scans, etc., to visualize the location of tumors and the extent of the disease. Additionally, a bronchoscopy or thoracoscopy is required to confirm a diagnosis.

The increasing cases of exposure to asbestos fibers, which cause inflammation and scarring within the pleura, are primarily driving the malignant pleural mesothelioma market. Apart from this, the rising incidences of several associated risk factors, including specific genetic mutations, smoking, exposure to high levels of radiation, etc., are also bolstering the market growth. Furthermore, the widespread adoption of immunotherapy as a treatment option for malignant pleural mesothelioma, since it modifies and improves the defense system's ability to recognize and destroy cancer cells, is creating a positive outlook for the market. Besides this, the escalating utilization of thoracentesis, a minimally invasive technique for removing excess fluid from the pleural space and relieving various symptoms, including shortness of breath and chest pain, is also augmenting the market growth. Moreover, several key players are making extensive investments in R&D activities to launch novel radiation therapy techniques that can reduce the risk of damage to healthy lung tissue and improve lung function. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene and photodynamic therapies, which can fight the disease more effectively with fewer side effects, thereby improving the quality of life for patients, is expected to drive the malignant pleural mesothelioma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the malignant pleural mesothelioma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for malignant pleural mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant pleural mesothelioma market in any manner.

Recent Developments

• In February 2024, RS Oncology revealed the first patient dosed in the phase 2 clinical study (MITOPE) with RSO-021 for malignant pleural mesothelioma. RSO-021 is a new small molecule therapy that permanently binds to mitochondrial peroxiredoxin 3 (PRX3).
• In February 2024, Ultimovacs ASA announced that the U.S. FDA had granted Fast Track designation to the company's therapeutic cancer vaccine UV1 in combination with nivolumab and ipilimumab for the treatment of patients with unresectable malignant pleural mesothelioma to boost overall survival, including first-line patients. The designation was given based on the outcomes of the Phase II clinical trial, NIPU, which evaluated UV1 in patients with unresectable malignant pleural mesothelioma.
• In November 2023, Polaris Group announced that it had begun the rolling submission of its Biologic License Application (BLA) for ADI-PEG 20 to the United States FDA for the systemic treatment of patients with malignant pleural mesothelioma with non-epithelioid histology, in combination with platinum and pemetrexed. This submission is based on the findings of a successful phase 3 study of ADI-PEG 20 in combination with a platinum agent and pemetrexed, which fulfilled both the primary and secondary objectives for progression-free survival and overall survival.
• In June 2023, Avenge Bio, Inc. declared that AVB-001 had been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA) for the purpose of treating mesothelioma patients.

Key Highlights:

• Malignant pleural mesothelioma accounts for 80–90 percent of all mesothelioma diagnoses.
• Approximately 70% of malignant pleural mesothelioma cases are related to determined asbestos exposure.
• Pleural mesothelioma affects approximately 2,500 people annually.
• In Europe, the annual incidence of malignant pleural mesothelioma is 1.83 per 100,000 people.
• Data suggest that malignant pleural mesothelioma has a 5-year survival rate of 12%.

Drugs:

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor used for the treatment of malignant pleural mesothelioma. It is indicated to uniquely harness the body's immune system to help rebuild anti-tumor immunity by inhibiting the interaction of PD-1 with its ligands.

CBP501 is a new synthetic peptide discovered by CanBas' unique phenotypic screen for G2 abrogation activities. CBP501 acts on cancer cells by increasing their sensitivity to cisplatin while having no effect on normal cells via numerous routes, including G2 checkpoint abrogation, which suppresses DNA damage repair, and modulation of calmodulin activity, which leads to enhanced platinum accumulation in tumor cells.

Lurbinectedin (PM1183) is a synthetic drug under clinical research. It selectively inhibits oncogenic transcription programs, a key factor in tumor development. In addition to targeting cancer cells, lurbinectedin suppresses oncogenic transcription in tumor-associated macrophages, reducing the generation of cytokines required for tumor growth.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the malignant pleural mesothelioma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the malignant pleural mesothelioma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current malignant pleural mesothelioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the malignant pleural mesothelioma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the malignant pleural mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the malignant pleural mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with malignant pleural mesothelioma across the seven major markets?
• What is the size of the malignant pleural mesothelioma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of malignant pleural mesothelioma?
• What will be the growth rate of patients across the seven major markets?
   

Malignant Pleural Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for malignant pleural mesothelioma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant pleural mesothelioma market?
• What are the key regulatory events related to the malignant pleural mesothelioma market?
• What is the structure of clinical trial landscape by status related to the malignant pleural mesothelioma market?
• What is the structure of clinical trial landscape by phase related to the malignant pleural mesothelioma market?
• What is the structure of clinical trial landscape by route of administration related to the malignant pleural mesothelioma market?